Subscribe to:
POZ magazine E-newsletters
POZ Personals Sign In / Join
Username:
Password:
African American Hub News
 

Back to home » News & Views » Treatment News


 

November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007


emailrssprint

July 7, 2008

Viramune Prescribing Information Updated

Children should be prescribed Viramune (nevirapine) based on the total surface area of their bodies rather than by weight, says a U.S. Food and Drug Administration (FDA) announcement regarding revisions to Viramune’s prescribing information. Recommendations regarding rashes and lead-in dosing and use of Viramune in people with liver impairment are also discussed.

Previous prescribing information for infants and children allowed health care providers to choose whether to provide Viramune based solely on a child’s weight or based on total body surface area (BSA), which is calculated using a formula that includes a child’s height and weight. Recent data, however, reveal that dosing based on BSA is more likely to result in desired blood levels of Viramune than is dosing based on weight. For this reason, it is now recommended that providers prescribe Viramune based only on BSA. Specifically, children 15 days and older should be given 150 milligrams of Viramune per meter squared of BSA once daily for the first 14 days, followed by 150 milligrams per meter squared of BSA twice daily thereafter.

The management of rash in adults and children is also reviewed in the new prescribing information. Current guidelines recommend starting Viramune at half the ultimate daily dose for the first 14 days and then switching to the full dose on day 15. The new prescribing information recommends that a person not increase their dose on day 15 if experiencing a rash. However, the lower lead-in dose should not be taken longer than 28 days. If a rash persists, Viramune should be switched for a comparable antiretroviral.

Lastly, the new prescribing information addresses the treatment of people with liver impairment. The new prescribing information recommends that people with moderate liver impairment avoid using Viramune. Previously, only those with severe liver impairment were cautioned to avoid using the drug. This is because people with either moderate or severe liver impairment can experience an accumulation of Viramune in their blood, which can cause serious side effects.

NEW! Scroll down to comment on this story.

emailrssprint

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team review all comments before they are posted. Please do not include either ":" or "@" in your comment.)

| Posting Rules

Previous Comments:

         


[Go to top]


Get Answers
What to do if you've just been diagnosed
How to find a support system
Things you should know before starting treatment
How to handle side effects and other concerns
How to tell someone you have HIV/AIDS

Blogs by African-Americans
Antonia
Felipe
Jeanette
Pinnace
Kate
Ferguson

Read the blogs
Overheard in the Forums
"I'm HIV positive and diabetic (as well as have high cholesterol) and some of my meds specify taking them with 'high fat foods' which I have to do twice a day. I've eaten as healthy as possible, but when it comes to high fat foods, I am in a quandary...about what to eat sometimes..."

from Nutrition & HIV


Join the forums

Real Health Poll
Question: How often do you order combo meals at fast food eateries?
Always
Sometimes
Never

Smart + Strong Network
POZ Magazine
POZ Personals
POZ Mentor
POZ ASO Directory
AIDSmeds
Real Health Magazine
TuSalud Magazine
ComboCards
Rx Info Cards
Also visit POZ on...
Facebook

MySpace

YouTube

[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertise/contact us | site map]
© 2008 Smart + Strong. All Rights Reserved. Terms of use and Your privacy